Skip to main content

Novartis AG

NVSEF
Exchange
OTC
Industry
Pharmaceutical Preparations
SEC CIK
0001114448

No open-market purchases or sales by Novartis AG insiders were filed in the last 90 days; 2 institutions reported holding it in 13F filings for Q2 2026, worth $6.28M in total; no superinvestor holds it.

Other share classesNVS

Holders of 5% or more of NVSEF

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Novartis AG, largest stake first. The change is against the holder's previous filing.

No holder currently reports owning 5% or more of Novartis AG on Schedule 13D or 13G.

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

Schedule 13D and 13G filings on Novartis AG, newest first.

No Schedule 13D or 13G filings on Novartis AG are on file.

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Novartis AG shares.

No Form 144 notices for Novartis AG are on file.